{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:44Z","timestamp":1790096924044,"version":"4.0.1"},"reference-count":75,"publisher":"American Chemical Society (ACS)","issue":"37","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA224033"],"award-info":[{"award-number":["CA224033"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The epidermal growth factor receptor (EGFR) is a frequently mutated protein kinase found in patients suffering from non-small cell lung cancer (NSCLC). Although therapeutic drugs targeting EGFR are available, not all patients respond to these drugs, and it is not yet known whether some clinically detected mutations are actionable. Although the oncogenicity of some mutants is well established, many mutants found in patients are not yet classified or classified as Variants of Uncertain Significance. For newly discovered rare mutants, strong evidence supporting their classification into oncogenic or benign is often lacking. Under such situations, multiple pieces of evidence can still help classification, even if each individual piece of evidence is weaker. Computational predictions have been considered as supporting information by the Standard Operating Procedure (SOP) of the Clinical Genome Resource\/Cancer Genomics Consortium\/Variant Interpretation for Cancer Consortium (ClinGen\/CGC\/VICC). The SOP considers predictions from multiple computational programs as providing only one piece of supporting information to avoid double counting because these programs share common approaches. A computational approach that explicitly accounts for the conformational effects of mutations via molecular dynamics (MD) simulation could add another piece of complementary supporting information. We tested the hypothesis that features of structural dynamics observed from MD simulation could help distinguish oncogenic from benign mutants. To this end, we performed three independent MD simulations lasting 1 \u03bcs each for wild-type EGFR and 32 of its oncogenic or benign mutants. We found that random forest machine-learning models constructed using suitable structural features were able to distinguish oncogenic and benign mutations effectively. Although we did not supply features of structural motifs commonly used by scientists to distinguish active and inactive conformations, our machine-learning approach identified and utilized some features associated with these motifs for classifying EGFR mutants.<\/jats:p>","DOI":"10.1021\/acsomega.6c08155","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:01:21Z","timestamp":1789041681000},"page":"56609-56622","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Oncogenic\nMutants of Epidermal Growth Factor\nReceptor in Lung Cancer by Molecular Dynamics Simulation with Machine\nLearning"],"prefix":"10.1021","volume":"11","author":[{"given":"Victor O.","family":"Anyanwu","sequence":"first","affiliation":[{"name":"University of Missouri-St Louis , , 1 University Boulevard , , ,","place":["St. Louis, Missouri, United States, 63121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Spiriti","sequence":"additional","affiliation":[{"name":"University of Missouri-St Louis , , 1 University Boulevard , , ,","place":["St. Louis, Missouri, United States, 63121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-4612","authenticated-orcid":true,"given":"Chung F.","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Missouri-St Louis , , 1 University Boulevard , , ,","place":["St. Louis, Missouri, United States, 63121"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026092211030907600_cit1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics,\n2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca-Cancer J. Clin"},{"key":"2026092211030907600_cit2","unstructured":"National Comprehensive Cancer Network (NCCN).\n          \n          Practice Guidelines in Oncology:\nNon\u2013Small Cell Lung Cancer.\nVersion 2.2012. NCCN (2012)."},{"key":"2026092211030907600_cit3","volume-title":"FDA Approves Erlotinib\nfor First-Line Treatment of Metastatic Non-Small Cell Lung Cancer\nwith EGFR Mutations. Vol. 2026","author":"U.S. Food and Drug Administration.","year":"2013"},{"key":"2026092211030907600_cit4","volume-title":"Office Director\nMemo: Application Number 201292Orig1s000 \u2013 Gilotrif (afatinib)","author":"Center for Drug Evaluation and Research.","year":"2013"},{"key":"2026092211030907600_cit5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances\nin lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026092211030907600_cit6","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever\nsmokers\u201d and are associated with sensitivity of tumors to gefitinib\nand erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S.\nA."},{"key":"2026092211030907600_cit7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying\nResponsiveness of Non-Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026092211030907600_cit8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth\nfactor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat.\nRev. Cancer"},{"key":"2026092211030907600_cit9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics\nPortal: An open platform for exploring multidimensional\ncancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discovery"},{"key":"2026092211030907600_cit10","doi-asserted-by":"publisher","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative\nanalysis of complex cancer genomics and\nclinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci.\nSignaling"},{"key":"2026092211030907600_cit11","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic\nand Clinical Data from the AACR Project GENIE Biopharma Collaborative\nin cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res."},{"key":"2026092211030907600_cit12","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database\nof somatic variants and clinical data\nfor cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"2026092211030907600_cit13","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue\nOf Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids\nRes."},{"key":"2026092211030907600_cit14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants\nin cancer (oncogenicity): Joint recommendations of Clinical Genome\nResource (ClinGen), Cancer Genomics Consortium (CGC), and Variant\nInterpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet. Med."},{"key":"2026092211030907600_cit15","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMsr1406261","article-title":"ClinGen - The clinical genome resource","volume":"372","author":"Rehm","year":"2015","journal-title":"N.\nEngl. J. Med."},{"key":"2026092211030907600_cit16","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.gim.2024.101213","article-title":"Assessment of the evidence yield for the calibrated PP3\/BP4 computational\nrecommendations","volume":"26","author":"Stenton","year":"2024","journal-title":"Genet. Med"},{"key":"2026092211030907600_cit17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare\nMissense Variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"2026092211030907600_cit18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/humu.23158","article-title":"PERCH:\nA Unified Framework for Disease Gene Prioritization","volume":"38","author":"Feng","year":"2017","journal-title":"Hum. Mutat"},{"key":"2026092211030907600_cit19","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1038\/s41467-020-19669-x","article-title":"Inferring the molecular and phenotypic impact\nof amino acid variants with MutPred2","volume":"11","author":"Pejaver","year":"2020","journal-title":"Nat. Commun"},{"issue":"3","key":"2026092211030907600_cit20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1471-2164-14-S3-S3","article-title":"Identifying\nMendelian disease genes with the variant effect scoring tool","volume":"14","author":"Carter","year":"2013","journal-title":"BMC Genomics"},{"key":"2026092211030907600_cit21","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1111\/1759-7714.14215","article-title":"Afatinib and osimertinib\nin lung adenocarcinoma harbored\nEGFR T751_I759delinsS mutation: A case report","volume":"12","author":"Fang","year":"2021","journal-title":"Thoracic Cancer"},{"key":"2026092211030907600_cit22","doi-asserted-by":"publisher","first-page":"13451","DOI":"10.3390\/ijms232113451","article-title":"EGFR T751_I759delinsN Mutation in\nExon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated\nPatient with NSCLC","volume":"23","author":"Chang","year":"2022","journal-title":"Int. J. Mol. Sci"},{"key":"2026092211030907600_cit23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222814","article-title":"Structural characterization\nof EGFR exon 19 deletion mutation using molecular dynamics simulation","volume":"14","author":"Tamirat","year":"2019","journal-title":"PLoS One"},{"key":"2026092211030907600_cit24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206588119","article-title":"Allele-specific activation, enzyme kinetics,\nand inhibitor sensitivities of EGFR exon 19 deletion mutations in\nlung cancer","volume":"119","author":"Brown","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"2026092211030907600_cit25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An Allosteric\nMechanism for Activation of the Kinase Domain of Epidermal Growth\nFactor Receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"2026092211030907600_cit26","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1158\/0008-5472.CAN-13-1145","article-title":"Cetuximab response of\nlung cancer-derived EGF receptor mutants is\nassociated with asymmetric dimerization","volume":"73","author":"Cho","year":"2013","journal-title":"Cancer\nRes."},{"key":"2026092211030907600_cit27","doi-asserted-by":"publisher","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization\nof epidermal growth factor receptor (EGFR) exon 20 insertion mutations\nin lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"2026092211030907600_cit28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug\nresponse in EGFR-mutant\nNSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2026092211030907600_cit29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding\nLandscape of Clinical Actionability for\nPatients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discovery"},{"key":"2026092211030907600_cit30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A precision\noncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"2026092211030907600_cit31","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: Improving access\nto variant interpretations and supporting\nevidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2026092211030907600_cit32","doi-asserted-by":"publisher","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: A\npublic database for medicinal chemistry, computational\nchemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2016","journal-title":"Nucleic\nAcids Res."},{"key":"2026092211030907600_cit33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/cancers13051120","article-title":"Structural basis\nfor the functional changes by EGFR exon 20 insertion mutations","volume":"13","author":"Tamirat","year":"2021","journal-title":"Cancers"},{"key":"2026092211030907600_cit34","doi-asserted-by":"publisher","first-page":"984503","DOI":"10.3389\/fphar.2022.984503","article-title":"EGFR exon 20 insertion\nvariants A763_Y764insFQEA and\nD770delinsGY confer favorable sensitivity to currently approved EGFR-specific\ntyrosine kinase inhibitors","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol"},{"key":"2026092211030907600_cit35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2417144121","article-title":"Biochemical\nanalysis of EGFR exon20 insertion variants insASV and insSVD and their\ninhibitor sensitivity","volume":"121","author":"Zhao","year":"2024","journal-title":"Proc. Natl. Acad. Sci.\nU. S. A"},{"key":"2026092211030907600_cit36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community\nknowledgebase for expert crowdsourcing the clinical\ninterpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat. Genet."},{"key":"2026092211030907600_cit37","doi-asserted-by":"publisher","first-page":"1054593","DOI":"10.3389\/fonc.2022.1054593","article-title":"NSCLC patients with\nrare EGFR Ex19del\/G724S mutation showed good response to afatinib\ncombined with chemotherapy treatment: A two-case report","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol"},{"key":"2026092211030907600_cit38","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","article-title":"The EGFR exon 19 mutant\nL747-A750&gt;P exhibits distinct sensitivity\nto tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026092211030907600_cit39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/1078-0432.CCR-19-2441","article-title":"The EGFR exon 19 mutant L747-A750&gt;P exhibits distinct\nsensitivity to tyrosine kinase inhibitors in lung adenocarcinoma\u2500letter","volume":"26","author":"Di Federico","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026092211030907600_cit40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.004","article-title":"Primary Resistance\nto Afatinib in\na Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations:\nS768I and V769L","volume":"13","author":"Niogret","year":"2018","journal-title":"J. Thorac. Oncol"},{"key":"2026092211030907600_cit41","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-15-1668","article-title":"Comprehensive genomic\nprofiling identifies frequent drug-sensitive\nEGFR exon 19 deletions in NSCLC not identified by prior molecular\ntesting","volume":"22","author":"Schrock","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2026092211030907600_cit42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/onc.2012.21","article-title":"Structural basis for\nthe altered drug sensitivities of non-small\ncell lung cancer-associated mutants of human epidermal growth factor\nreceptor","volume":"32","author":"Yoshikawa","year":"2013","journal-title":"Oncogene"},{"key":"2026092211030907600_cit43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein\nmodelling by satisfaction of spatial\nrestraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol"},{"key":"2026092211030907600_cit44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev.biophys.29.1.291","article-title":"Comparative protein\nstructure modeling of genes and genomes","volume":"29","author":"Marti-Renom","year":"2000","journal-title":"Annu.\nRev. Biophys. Biomol. Struct."},{"key":"2026092211030907600_cit45","doi-asserted-by":"publisher","first-page":"5.6.1","DOI":"10.1002\/cpbi.3","article-title":"Comparative protein\nstructure modeling using MODELLER","volume":"54","author":"Webb","year":"2016","journal-title":"Curr. Protoc.\nBioinform."},{"key":"2026092211030907600_cit46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bpj.2012.07.042","article-title":"Inclusion\nof many-body effects in the additive CHARMM protein CMAP potential\nresults in enhanced cooperativity of \u03b1-helix and \u03b2-hairpin\nformation","volume":"103","author":"Best","year":"2012","journal-title":"Biophys. J"},{"key":"2026092211030907600_cit47","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the\nadditive CHARMM all-atom protein force field\ntargeting improved sampling of the backbone \u03c6, \u03c8 and side-chain\n\u03c71 and \u03c72 Dihedral Angles","volume":"8","author":"Best","year":"2012","journal-title":"J. Chem.\nTheory Comput."},{"key":"2026092211030907600_cit48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: An improved\nforce field for folded and intrinsically disordered\nproteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. Methods"},{"key":"2026092211030907600_cit49","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular\nsimulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."},{"key":"2026092211030907600_cit50","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1063\/1.1480013","article-title":"Novel generalized\nBorn methods","volume":"116","author":"Lee","year":"2002","journal-title":"J. Chem. Phys"},{"key":"2026092211030907600_cit51","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/jcc.10272","article-title":"New Analytical Approximation\nto the Standard Molecular Volume Definition and Its Application to\nGeneralized Born Calculations","volume":"24","author":"Lee","year":"2003","journal-title":"J. Comput. Chem"},{"key":"2026092211030907600_cit52","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison\nof Simple Potential Functions for Simulating Liquid Water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys"},{"key":"2026092211030907600_cit53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/jcph.1999.6201","article-title":"NAMD2: Greater Scalability for Parallel Molecular Dynamics","volume":"151","author":"Kale\u0301","year":"1999","journal-title":"J. Comput. Biophys. Chem."},{"key":"2026092211030907600_cit54","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics\nwith NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput.\nChem."},{"key":"2026092211030907600_cit55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical\nIntegration of the Cartesian\nEquations of Motion of a System with Constraints: Molecular Dynamics\nof n-Alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys"},{"key":"2026092211030907600_cit56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational\nplasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"2026092211030907600_cit57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1109\/18.61115","article-title":"Divergence\nMeasures Based on the Shannon Entropy","volume":"37","author":"Lin","year":"1991","journal-title":"IEEE\nTrans. Inf. Theory"},{"key":"2026092211030907600_cit58","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/bip.360221211","article-title":"Dictionary of Protein Secondary Structure: Pattern\nRecognition of Hydrogen Bonded and Geometrical Features","volume":"22","author":"Kabsch","year":"1983","journal-title":"Biopolymers"},{"key":"2026092211030907600_cit59","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bpj.2015.08.015","article-title":"MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics\nTrajectories","volume":"109","author":"McGibbon","year":"2015","journal-title":"Biophys. J."},{"key":"2026092211030907600_cit60","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1073\/pnas.1814279116","article-title":"Defining a new nomenclature\nfor the structures of active\nand inactive kinases","volume":"116","author":"Modi","year":"2019","journal-title":"Proc. Natl. Acad. Sci.\nU. S. A"},{"key":"2026092211030907600_cit61","doi-asserted-by":"publisher","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: A web resource for structural classification\nof protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic\nAcids Res"},{"key":"2026092211030907600_cit62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn"},{"key":"2026092211030907600_cit63","first-page":"2825","article-title":"Scikit-learn: Machine\nlearning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res"},{"key":"2026092211030907600_cit64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1023\/A:1024068626366","article-title":"Inference for the Generalization\nError","volume":"52","author":"Nadeau","year":"2003","journal-title":"Mach. Learn"},{"key":"2026092211030907600_cit65","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural\nfeatures of the protein kinase domain and targeted binding by small-molecule\ninhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem"},{"key":"2026092211030907600_cit66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: Conserved\nfeatures and deduced phylogeny of the catalytic domains","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"2026092211030907600_cit67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2011.03.004","article-title":"Catalytic Control in the EGF Receptor and Its Connection to General\nKinase Regulatory Mechanisms","volume":"42","author":"Jura","year":"2011","journal-title":"Mol. Cell"},{"key":"2026092211030907600_cit68","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth\nfactor receptor kinase domain alone and in complex with a 4-anilinoquinazoline\ninhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem"},{"key":"2026092211030907600_cit69","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.molcel.2009.04.034","article-title":"The Juxtamembrane Region of the EGF Receptor Functions\nas an Activation Domain","volume":"34","author":"Red Brewer","year":"2009","journal-title":"Mol. Cell"},{"key":"2026092211030907600_cit70","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1073\/pnas.82.15.5000","article-title":"Protein states and proteinquakes","volume":"82","author":"Ansari","year":"1985","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"key":"2026092211030907600_cit71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of\nSequence Variants in Cancer: A Joint Consensus Recommendation of the\nAssociation for Molecular Pathology, American Society of Clinical\nOncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"2026092211030907600_cit72","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2046-4053-2-10","article-title":"Survival of patients with non-small cell lung cancer\nwithout treatment: a systematic review and meta-analysis","volume":"2","author":"Wao","year":"2013","journal-title":"Syst. Rev"},{"key":"2026092211030907600_cit73","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","article-title":"Treatment\nof brain metastases","volume":"33","author":"Lin","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"2026092211030907600_cit74","volume-title":"U.S. Cancer Statistics Lung Cancer Stat Bite","author":"U.S. Centers for Disease Control and Prevention.","year":"2025"},{"key":"2026092211030907600_cit75","doi-asserted-by":"publisher","first-page":"1451230","DOI":"10.3389\/fonc.2024.1451230","article-title":"Targeted therapy\nof non-small cell lung cancer: mechanisms and clinical trials","volume":"14","author":"Yu","year":"2024","journal-title":"Front. Oncol"}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.6c08155","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/37\/56609\/68468993\/acsomega.6c08155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/37\/56609\/68468993\/acsomega.6c08155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:14:02Z","timestamp":1790093642000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/11\/37\/56609\/5427544\/Predicting-Oncogenic-Mutants-of-Epidermal-Growth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":75,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.6c08155","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}